Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 2/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 7/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16121414 | 0.88 | CBFB (0.60) | CBFBCACNA1HCACNA1GTRPV1CACNA1C | |
| SCHEMBL4188519 | 0.88 | CBFB (0.50) | CBFBCACNA1HCACNA1GCACNA1CCACNA1B | |
| SCHEMBL4189049 | 0.88 | CBFB (0.47) | CBFBCACNA1HCACNA1GCACNA1CCACNA1B | |
| SCHEMBL16471221 | 0.86 | CBFB (0.47) | CBFBCACNA1HCACNA1GTRPV1CACNA1C | |
| SCHEMBL4189155 | 0.84 | CBFB (0.53) | CBFBCACNA1HCACNA1GTRPV1CACNA1C | |
| SCHEMBL4174467 | 0.83 | CBFB (0.58) | CBFBTRPV1 | |
| SCHEMBL4187103 | 0.83 | CBFB (0.60) | CBFBCACNA1HCACNA1GCACNA1CCACNA1B | |
| SCHEMBL4180008 | 0.82 | TRPV1 (0.54) | CBFBCACNA1HCACNA1GTRPV1CACNA1C | |
| SCHEMBL4181897 | 0.82 | AURKA (0.46) | CBFBTRPV1KIF11 | |
| SCHEMBL904568 | 0.80 | CBFB (0.56) | CBFBCACNA1HCACNA1GTRPV1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861387-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | DAE WOONG PHARMA (KR) | 2014-04-16 | — | — | EP | claimed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | claimed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| EP-1861387-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | DAE WOONG PHARMA (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | TRPV1, TRPA1, BDKRB2 | CBFB 1891/4885CACNA1H 522/4885CACNA1G 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.